Howard W. Robin Sells 16,278 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock

Nektar Therapeutics (NASDAQ:NKTR) CEO Howard W. Robin sold 16,278 shares of the company’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $1.01, for a total value of $16,440.78. Following the completion of the sale, the chief executive officer now owns 832,080 shares of the company’s stock, valued at approximately $840,400.80. This trade represents a 1.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Nektar Therapeutics Stock Up 2.5 %

Shares of NASDAQ NKTR opened at $1.04 on Friday. Nektar Therapeutics has a 12 month low of $0.42 and a 12 month high of $1.93. The company has a market cap of $190.92 million, a price-to-earnings ratio of -1.20 and a beta of 0.61. The business has a fifty day simple moving average of $1.28 and a 200-day simple moving average of $1.32.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Piper Sandler started coverage on shares of Nektar Therapeutics in a report on Monday, November 4th. They issued an “overweight” rating and a $7.00 price target for the company. BTIG Research reiterated a “buy” rating and issued a $4.00 target price on shares of Nektar Therapeutics in a report on Monday, September 30th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Nektar Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $3.50.

Institutional Trading of Nektar Therapeutics

A number of hedge funds have recently bought and sold shares of the company. State Board of Administration of Florida Retirement System purchased a new position in shares of Nektar Therapeutics in the first quarter worth approximately $63,000. Lynx1 Capital Management LP boosted its stake in Nektar Therapeutics by 7.2% in the 1st quarter. Lynx1 Capital Management LP now owns 2,068,842 shares of the biopharmaceutical company’s stock worth $1,933,000 after purchasing an additional 139,644 shares during the period. SG Americas Securities LLC grew its position in Nektar Therapeutics by 63.0% during the 2nd quarter. SG Americas Securities LLC now owns 73,352 shares of the biopharmaceutical company’s stock worth $91,000 after purchasing an additional 28,338 shares in the last quarter. Values First Advisors Inc. purchased a new position in Nektar Therapeutics during the 2nd quarter worth approximately $56,000. Finally, Bank of New York Mellon Corp raised its stake in Nektar Therapeutics by 2,822.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 551,535 shares of the biopharmaceutical company’s stock valued at $684,000 after purchasing an additional 532,663 shares during the period. 75.88% of the stock is owned by hedge funds and other institutional investors.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.